Infections, Bacterial Clinical Trial
Official title:
A Phase 1, Randomized, Single Blind Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of an Oral Contraceptive Containing Norethindrone and Ethinyl Estradiol When Co-administered With GSK1322322 in Healthy Adult Women of Childbearing Age Who Are of Non-Childbearing Potential Due to Surgical Sterilization or IUD Placement (PDF112163)
This study is being conducted to confirm that GSK1322322 has no negative impact on hormone levels and contraceptive efficacy when co-administered with a frequently prescribed oral contraceptive thereby to facilitate the use of GSK1322322 in women of child-bearing potential receiving oral contraceptive (OC) pre-infection. This study is designed to investigate steady-state plasma ethinyl estradiol (EE) and norethindrone (NE) pharmacokinetic (PK) following administration of Ortho-Novum (EE/NE) 1 tablet every 24 hours (q24h) fed with and without GSK1322322 1500 milligram (mg) q12h fed. Each subject will participate in the study for approximately 12 weeks: a 30 day screening period, 4-week run-in period, three 7 day treatment periods, and a 3-5 day follow-up period. The study is planned to enroll approximately 24 subjects (18 active/6 placebo).
Please note that Ortho-Novum is a registered trademark of Ortho Pharmaceutical Corporation. ;
Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04079790 -
Pharmacokinetics of Gepotidacin Tablets in Adults and Adolescents Subjects
|
Phase 1 | |
Completed |
NCT01934205 -
To Evaluate Plasma and Pulmonary Pharmacokinetics of GSK2140944
|
Phase 1 | |
Not yet recruiting |
NCT02177721 -
Clinical Benefit, Safety and PK of Raxibacumab in Subjects Exposed to Bacillus Anthracis
|
Phase 4 | |
Suspended |
NCT01132417 -
In Vitro Activity of Tigecycline Among Key Bacterial Pathogens Exhibiting Multidrug Resistance
|
N/A | |
Completed |
NCT00539994 -
Retapamulin Ointment in Healthy Adults Nasally Colonized With Staphylococcus Aureus
|
Phase 2 | |
Completed |
NCT01610388 -
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Oral and Intravenous GSK1322322 in Healthy Subjects
|
Phase 1 | |
Completed |
NCT01262885 -
A Randomized, Single Blind, Placebo Controlled Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single Oral Doses and Repeat Escalating Oral Doses of GSK2251052 in Healthy Adult Subjects
|
Phase 1 | |
Completed |
NCT00427141 -
A Three-Part Study Of GSK580416 In Healthy Subjects
|
Phase 1 | |
Completed |
NCT04620486 -
Effect of BPA on Anchor Antibiotic Continuity in the ED: Randomized Controlled Trial
|
N/A | |
Recruiting |
NCT06451172 -
Novel Antisense Oligonucleotide Eye Drops for Treating Antibiotic-Resistant Bacterial Keratitis
|
Early Phase 1 | |
Not yet recruiting |
NCT06440304 -
Therapeutic Options for CRAB
|
Phase 4 | |
Completed |
NCT02292498 -
Thermal Imaging to Diagnose and Monitor Suspected Bacterial Infections
|
N/A | |
Completed |
NCT01587768 -
WEUKBRE5555: IMI PROTECT(Work Package 2): Liver Injury & Antibiotics
|
N/A | |
Withdrawn |
NCT01039610 -
A Single Center Four Part Study in Healthy Adult Subjects to Evaluate: the Safety, Tolerability and Pharmacokinetics of a Single Oral Dose and Repeat Escalating Oral Doses of GSK945237; the Effect of Linezolid on Hematology Safety Parameters; and the Effects of GSK945237 and Moxifloxacin on QTc.
|
Phase 1 | |
Completed |
NCT00259909 -
Observational Study Of An Electronic Questionnaire In Patients With Chronic Obstructive Pulmonary Disease (COPD)
|
N/A | |
Completed |
NCT00828867 -
Single Dose Escalation First Time in Human PK Study
|
Phase 1 | |
Completed |
NCT01431989 -
Amoxicillin Bioequivalence Study Brazil - Fast
|
Phase 1 | |
Completed |
NCT02778672 -
Thermal Imaging of the Lung on a Smartphone to Differentiate Bacterial From Non Bacterial Causes of Pneumonia
|
N/A | |
Completed |
NCT00896558 -
A Repeat Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK1322322 in Healthy Subjects
|
Phase 1 | |
Completed |
NCT02045797 -
Dose-Ranging Study of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
|
Phase 2 |